These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 719602)
1. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602 [TBL] [Abstract][Full Text] [Related]
2. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels]. Heilmann P; Wagner P; Nawroth PP; Ziegler R Med Klin (Munich); 2001 Jul; 96(7):371-7. PubMed ID: 11494911 [TBL] [Abstract][Full Text] [Related]
3. Determination of mitotane (o,p-DDD) and its metabolites o,p-DDA and o,p-DDE in plasma by high-performance liquid chromatography. Andersen A; Kasperlik-Zaluska AA; Warren DJ Ther Drug Monit; 1999 Jun; 21(3):355-9. PubMed ID: 10365653 [TBL] [Abstract][Full Text] [Related]
4. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up. Kasperlik-Zaluska AA; Cichocki A J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038 [TBL] [Abstract][Full Text] [Related]
5. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro. Theile D; Haefeli WE; Weiss J Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188 [TBL] [Abstract][Full Text] [Related]
6. A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients. Garg MB; Sakoff JA; Ackland SP J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2201-5. PubMed ID: 21719363 [TBL] [Abstract][Full Text] [Related]
7. [The effects of o,p'-DDD on human adrenal steroid synthesis]. Ojima M; Saito M; Fukuchi S Nihon Naibunpi Gakkai Zasshi; 1984 Jul; 60(7):852-71. PubMed ID: 6094274 [TBL] [Abstract][Full Text] [Related]
8. A high-pressure liquid chromatographic method for measuring mitotane [1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethene in plasma. Andersen A; Warren DJ; Nome O; Vesterhus L; Slørdal L Ther Drug Monit; 1995 Oct; 17(5):526-31. PubMed ID: 8585118 [TBL] [Abstract][Full Text] [Related]
9. The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia. Gebhardt DO; Moolenaar AJ; van Seters AP; van der Velde EA; Gevers Leuven JA Cancer Chemother Pharmacol; 1992; 29(4):331-4. PubMed ID: 1537084 [TBL] [Abstract][Full Text] [Related]
10. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses. Benecke R; Keller E; Vetter B; de Zeeuw RA Eur J Clin Pharmacol; 1991; 41(3):259-61. PubMed ID: 1748144 [TBL] [Abstract][Full Text] [Related]
11. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975 [TBL] [Abstract][Full Text] [Related]
12. Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment. Moolenaar AJ; van Slooten H; van Seters AP; Smeenk D Cancer Chemother Pharmacol; 1981; 7(1):51-4. PubMed ID: 7340988 [TBL] [Abstract][Full Text] [Related]
13. Complete remission of metastasized adrenocortical carcinoma under o,p'-DDD. Kornely E; Schlaghecke R Exp Clin Endocrinol; 1994; 102(1):50-3. PubMed ID: 8005209 [TBL] [Abstract][Full Text] [Related]
14. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. Cusato J; De Francia S; Allegra S; Carrella S; Pirro E; Piccione FM; De Martino F; Ferrero A; Daffara FC; Terzolo M; Berruti A; Di Carlo F; Tampellini M; D'Avolio A J Pharm Pharmacol; 2017 Nov; 69(11):1524-1530. PubMed ID: 28809444 [TBL] [Abstract][Full Text] [Related]
15. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. van Slooten H; Moolenaar AJ; van Seters AP; Smeenk D Eur J Cancer Clin Oncol; 1984 Jan; 20(1):47-53. PubMed ID: 6537915 [TBL] [Abstract][Full Text] [Related]
16. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Robinson BG; Hales IB; Henniker AJ; Ho K; Luttrell BM; Smee IR; Stiel JN Clin Endocrinol (Oxf); 1987 Oct; 27(4):437-44. PubMed ID: 2830062 [TBL] [Abstract][Full Text] [Related]
17. Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review. Boven E; Vermorken JB; van Slooten H; Pinedo HM Cancer; 1984 Jan; 53(1):26-9. PubMed ID: 6360329 [TBL] [Abstract][Full Text] [Related]
19. Significant regression of the tumor combined with the high level of plasma cortisol by low-dose administration of O, p'-DDD in a case with Cushing's syndrome caused by adrenocortical carcinoma. Otokida K; Nakamura M; Takeda M; Ito T; Kato M; Masuda T; Tashiro A Tohoku J Exp Med; 1986 Dec; 150(4):407-15. PubMed ID: 3564003 [TBL] [Abstract][Full Text] [Related]
20. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. Lim MC; Tan YO; Chong PY; Cheah JS Ann Acad Med Singap; 1990 Jul; 19(4):540-4. PubMed ID: 2171414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]